Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of BI 730357 on the Pharmacokinetics of Rosuvastatin, Digoxin, Metformin and Furosemide Given as a Cocktail - an Open-label, Non-randomised, 2-period Fixed-sequence Trial in Healthy Subjects

Next Previous
Trial Profile

The Effect of BI 730357 on the Pharmacokinetics of Rosuvastatin, Digoxin, Metformin and Furosemide Given as a Cocktail - an Open-label, Non-randomised, 2-period Fixed-sequence Trial in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 730357 (Primary) ; Digoxin; Furosemide; Metformin; Rosuvastatin
  • Indications Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 27 Sep 2022 Results assessing the effect of transporter-mediated drug interac-tions of BI 730357 in healthy volunteers using atransporter probe cocktail consisting of digoxin, furosemide, metformin and rosuvastatin presented at the 2022 American College of Clinical Pharmacology Annual Meeting
  • 14 Jan 2021 Status changed from active, no longer recruiting to completed.
  • 30 Nov 2020 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top